These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 11785702)
21. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. White PJ; Anastasopoulos F; Pouton CW; Boyd BJ Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730 [TBL] [Abstract][Full Text] [Related]
22. Transdermal iontophoretic drug delivery: advances and challenges. Ita K J Drug Target; 2016; 24(5):386-91. PubMed ID: 26406291 [TBL] [Abstract][Full Text] [Related]
23. Gene and antisense delivery in alcoholism research. Israel Y; Crews FT; Thurman RG; Tu GC; Garver E; Ponnappa B; Karahanian E; Rubin R; Hoplight B; Sethna M; Hanes R; Wilkie MB; Wheeler MD Alcohol Clin Exp Res; 2002 Apr; 26(4):582-5. PubMed ID: 11981136 [TBL] [Abstract][Full Text] [Related]
26. Dual-Phase Iontophoresis for the Delivery of Antisense Oligonucleotides. Gibson DJ; Tuli SS; Schultz GS Nucleic Acid Ther; 2017 Aug; 27(4):238-250. PubMed ID: 28375679 [TBL] [Abstract][Full Text] [Related]
27. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938 [TBL] [Abstract][Full Text] [Related]
28. Intraocular delivery of oligonucleotides. Gomes Dos Santos AL; Bochot A; Fattal E Curr Pharm Biotechnol; 2005 Feb; 6(1):7-15. PubMed ID: 15727552 [TBL] [Abstract][Full Text] [Related]
30. Identification of peptides for tissue-specific delivery. Heemskerk H Methods Mol Biol; 2012; 867():379-92. PubMed ID: 22454074 [TBL] [Abstract][Full Text] [Related]
31. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers. Jääskeläinen I; Lappalainen K; Honkakoski P; Urtti A Methods Enzymol; 2004; 387():210-30. PubMed ID: 15172166 [No Abstract] [Full Text] [Related]
32. Dissolving microneedles for transdermal drug delivery: Advances and challenges. Ita K Biomed Pharmacother; 2017 Sep; 93():1116-1127. PubMed ID: 28738520 [TBL] [Abstract][Full Text] [Related]
33. Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin. Nguyen HX; Bozorg BD; Kim Y; Wieber A; Birk G; Lubda D; Banga AK Eur J Pharm Biopharm; 2018 Aug; 129():88-103. PubMed ID: 29800617 [TBL] [Abstract][Full Text] [Related]
34. Ex vivo evaluation of a microneedle array device for transdermal application. Indermun S; Choonara YE; Kumar P; du Toit LC; Modi G; van Vuuren S; Luttge R; Pillay V Int J Pharm; 2015 Dec; 496(2):351-9. PubMed ID: 26453791 [TBL] [Abstract][Full Text] [Related]
35. Iontophoretic drug delivery system: a review. Semalty A; Semalty M; Singh R; Saraf SK; Saraf S Technol Health Care; 2007; 15(4):237-45. PubMed ID: 17673833 [TBL] [Abstract][Full Text] [Related]
36. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943 [TBL] [Abstract][Full Text] [Related]